Live Breaking News & Updates on Stephen Mayo

Stay updated with breaking news from Stephen mayo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Mizuho Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $179.00

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lifted by Mizuho from $145.00 to $179.00 in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. UBS Group raised their price […] ....

New Jersey , United States , Stephen Mayo , Royal Bank , Sarepta Therapeutics Company Profile , Sarepta Therapeutics Inc , Securities Exchange Commission , Vanguard Group Inc , Investment Management , Capula Management Ltd , Jersey Common Pension Fund , Sarepta Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Stephen Mayo , Exchange Commission , Director Kathryn Jean Boor , Mahoney Asset Management , Management Ltd , Sarepta Therapeutics Daily ,

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.9%

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) shot up 5.9% during mid-day trading on Wednesday . The stock traded as high as $124.37 and last traded at $124.01. 550,813 shares traded hands during trading, a decline of 43% from the average session volume of 972,684 shares. The stock had previously closed at […] ....

Hans Lennart Rudolf Wigzell , Stephen Mayo , Cantor Fitzgerald , Sarepta Therapeutics Company Profile , Hudson Capital Management , Royal Bank , Securities Exchange Commission , Wealth Enhancement Advisory Services , Sarepta Therapeutics Inc , Altfest Lj Co , Sarepta Therapeutics , Get Free Report , Director Hans Lennart Rudolf Wigzell , Exchange Commission , Director Stephen Mayo , Capital Management , Enhancement Advisory Services , Sarepta Therapeutics Daily ,

FY2024 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Decreased by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Stock analysts at William Blair reduced their FY2024 EPS estimates for Sarepta Therapeutics in a research report issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $6.66 for the year, down from their previous […] ....

William Blair , Stephen Mayo , Ian Michael Estepan , Partners Investment Advisory , Montaga Associates Inc , Principal Securities Inc , Sarepta Therapeutics Inc , Sarepta Therapeutics Company Profile , Royal Bank , Europe London , Securities Exchange Commission , Mather Group , Sarepta Therapeutics , Free Report , Sarepta Therapeutic , Get Free Report , Therapeutics Trading Down , Street Partners Investment Advisory , Director Stephen Mayo , Exchange Commission , Michael Estepan , Sarepta Therapeutics Daily , Nasdaq Srpt , Earnings Estimates ,